EFFICACY AND SAFETY FROM A PHASE 2B TRIAL OF SM04690, A NOVEL, INTRA-ARTICULAR, WNT PATHWAY INHIBITOR FOR THE TREATMENT OF OSTEOARTHRITIS OF THE KNEE

被引：9

作者：

Yazici, Y. ^{[1
]}

McAlindon, T. E. ^{[2
]}

Gibofsky, A. ^{[3
,4
]}

Lane, N. E. ^{[5
]}

Latterman, C. ^{[6
]}

Skrepnik, N. ^{[7
]}

Swearingen, C. J. ^{[1
]}

DiFrancesco, A. ^{[1
]}

Tambiah, J. R. ^{[1
]}

Hochberg, M. C. ^{[8
]}

机构：

[1] Samumed, San Diego, CA USA

[2] Tufts Med Ctr, Boston, MA 02111 USA

[3] Weill Cornell Med Coll, New York, NY USA

[4] Hosp Special Surg, 535 E 70th St, New York, NY 10021 USA

[5] Univ Calif Davis, Med Ctr, Davis, CA USA

[6] Harvard Univ, Brigham & Womens Hosp, Cambridge, MA 02138 USA

[7] Tucson Orthoped Inst, Tucson, AZ USA

[8] Univ Maryland, Sch Med, Baltimore, MD 21201 USA

来源：

OSTEOARTHRITIS AND CARTILAGE | 2019年 / 27卷

关键词：

D O I：

10.1016/j.joca.2019.02.566

中图分类号：

R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学（修复外科学）];

学科分类号：

摘要：

728

引用

页码：S503 / S503

页数：1

共 50 条

[41] RESULTS FROM A 52 WEEK RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY OF A NOVEL, WNT PATHWAY INHIBITOR (SM04690) FOR KNEE OSTEOARTHRITIS TREATMENT
Yazici, Y.
McAlindon, T.
Gibofsky, A.
Lane, N.
Clauw, D.
Swearingen, C.
DiFrancesco, A.
Tambiah, J.
Hochberg, M.
ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1146 - 1147
[42] LORECIVIVINT (SM04690), AN INTRA-ARTICULAR, SMALL-MOLECULE CLK/DYRK1A INHIBITOR THAT MODULATES THE WNT PATHWAY, AS A POTENTIAL TREATMENT FOR MENISCAL INJURIES
Seo, T.
Deshmukh, V.
Yazici, Y.
ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1331 - 1331
[43] LORECIVIVINT (SM04690), AN INTRA-ARTICULAR, SMALL-MOLECULE CLK/DYRK1A INHIBITOR THAT MODULATES THE WNT PATHWAY, AS A POTENTIAL TREATMENT FOR MENISCAL INJURIES
Seo, T.
Deshmukh, V.
Yazici, Y.
OSTEOARTHRITIS AND CARTILAGE, 2021, 29 : S101 - S102
[44] LORECIVIVINT (SM04690), AN INTRA-ARTICULAR, SMALL-MOLECULE CLK2/DYRK1A INHIBITOR THAT MODULATES THE WNT PATHWAY, AS A POTENTIAL TREATMENT FOR MENISCAL INJURIES
Seo, T.
Deshmukh, V.
Yazici, Y.
ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 416 - 417
[45] LORECIVIVINT (SM04690), AN INTRA-ARTICULAR, SMALL-MOLECULE CLK/DYRK1A INHIBITOR THAT MODULATES THE WNT PATHWAY, AS A POTENTIAL TREATMENT FOR MENISCAL INJURIES
Seo, T.
Deshmukh, V.
Yazici, Y.
OSTEOPOROSIS INTERNATIONAL, 2020, 31 (SUPPL 1) : S595 - S596
[46] JOINT SPACE WIDTH INCLUSION CRITERIA CAN REDUCE KNEE OSTEOARTHRITIS TRIAL HETEROGENEITY: POST-HOC DATA FROM A PHASE 2 TRIAL OF WNT PATHWAY INHIBITOR, SM04690
Conaghan, P.
Tambiah, J.
Swearingen, C. J.
Kennedy, S.
Bowes, M.
Brett, A.
Lattermann, C.
OSTEOARTHRITIS AND CARTILAGE, 2018, 26 : S274 - S275
[47] OPTIMIZING SUBJECT SELECTION IN KNEE OSTEOARTHRITIS CLINICAL TRIALS BY RADIOGRAPHIC JOINT SPACE WIDTH: POST-HOC CLINICAL RESPONSE ANALYSIS FROM A PHASE 2B TRIAL OF WNT PATHWAY INHIBITOR, SM04690
Kennedy, Sarah
Swearingen, Christopher
Tambiah, Jeyanesh
Conaghan, Philip G.
ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 144 - 144
[48] Analysis of Pain and Function Components in Omeract-Oarsi Strict Responders from a Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study of a Novel, Intra-Articular, Injectable, Wnt Inhibitor (SM04690) in the Treatment of Osteoarthritis of the Knee
Strand, Vibeke
Swearingen, Christopher J.
Simsek, Ismail
DiFrancesco, Anita
Tambiah, Jeymi
Yazici, Yusuf
ARTHRITIS & RHEUMATOLOGY, 2016, 68
[49] TREATMENT WITH LORECIVIVINT, A NOVEL, INTRA-ARTICULAR CLK/DYRK1A INHIBITOR THAT MODULATES THE WNT PATHWAY, LED TO IMPROVED RESPONDER OUTCOMES IN SUBJECTS WITH KNEE OSTEOARTHRITIS: A POST HOC ANALYSIS OF A PHASE 2B TRIAL
Yazici, Y.
Kennedy, S.
Swearingen, C. J.
Tambiah, J.
OSTEOARTHRITIS AND CARTILAGE, 2020, 28 : S358 - S358
[50] AN INTEGRATED SAFETY ANALYSIS OF LORECIVIVINT, A NOVEL, INTRA-ARTICULAR CLK/DYRKIA INHIBITOR THAT MODULATES THE WNT PATHWAY, IN SUBJECTS WITH KNEE OSTEOARTHRITIS
Simsek, I.
Swearingen, C. J.
Kennedy, S.
Tambiah, J.
Yazici, Y.
Lane, N. E.
Hochberg, M. C.
OSTEOARTHRITIS AND CARTILAGE, 2020, 28 : S376 - S377

← 1 2 3 4 5 →